Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | AGXT | P21549 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31225807 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL31225894 | 0.84 | SMN1; SMN2 (0.49) | SMN1; SMN2MAOBHCAR2ALDH1A1MAOA | |
| SCHEMBL6937307 | 0.83 | SMN1; SMN2 (0.67) | SMN1; SMN2POLBALDH1A1MAPK1 | |
| SCHEMBL30692683 | 0.81 | SLC7A5 (0.55) | MAOBRAB9AIDO1AGXTALDH1A1 | |
| SCHEMBL74878 | 0.81 | SLC7A5 (0.55) | MAOBRAB9AIDO1AGXTALDH1A1 | |
| SCHEMBL17674564 | 0.81 | CYP19A1 (0.55) | SMN1; SMN2MAOBSRCNR4A2ALDH1A1 | |
| SCHEMBL31226055 | 0.80 | KMT2A (0.55) | SMN1; SMN2RAB9APOLBALDH1A1 | |
| SCHEMBL2485584 | 0.79 | MAOB (0.58) | SMN1; SMN2MAOBRAB9AHCAR2 | |
| SCHEMBL29020276 | 0.76 | MMP1 (0.39) | MAOBNR4A2HCAR2IDO1AGXT | |
| SCHEMBL1426756 | 0.75 | MAOB (0.51) | MAOBIDO1AGXTMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | ADAXION THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2024259007-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | SIGLEC7, SIGLEC9, CD2BP2 | SMN1; SMN2 2857/4885MAOB 2158/4885RAB9A 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.